Thursday, February 20, 2025

Upperton Pharma Solutions appoints T-SQUARED for build of new development and manufacturing facility in Nottingham

Upperton Pharma Solutions, a contract development and manufacturing organisation (CDMO), has appointed T-SQUARED as the Principal Design and Build contractor for its new Development and GMP Manufacturing headquarters in Nottingham.

The new site will be built at the recently opened Trent Gateway Business Park in Beeston, situated less than two miles from Upperton’s current headquarters in Albert Einstein Centre, Nottingham Science Park. The 50,000 ft² facility marks a significant expansion for the company and will incorporate ten new GMP manufacturing suites, Quality Control laboratories and dedicated Analytical and Formulation Development laboratories including Pilot Plant facilities.

The appointment of T-SQUARED as the principal contractor is a hugely important milestone for the new site development project, which is expected to complete towards the end of 2023.

Upperton CEO, Nikki Whitfield, said: “Our new state-of-the-art facility is being built to satisfy our increasing customer demand to extend our service offering further along the drug development pathway.

“The design and build of a site that can meet our clients’ requirements from a complexity, scale and potency perspective, whilst meeting all the necessary regulatory requirements, is an exciting but significant project therefore we are delighted we have been able to appoint industry leader T-SQUARED to partner with us on this task.’’

The Trent Gateway site will have the capability to develop and manufacture a range of dosage forms including oral solid dosage forms, liquids, semi-solids, nasal and inhaled products, allowing it to support early formulation development and provide clinical trial supplies from Phase 1 to Phase 3. The GMP facility layout, equipment and containment capabilities have also been designed to align with larger scale process trains, supporting batch scales of up to 250kg.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemic having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £33.60 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.









Latest news

Related news

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close